Literature Search Queries

MEDLINE (Dialog)
PubMed

I. Search Period for Target Data: July 01, 2007–December 31, 2011

Patients: Limited to HCC (excluding animal studies)

Language: Limited to English, Japanese literature

*Newly established CQs were searched from January 01, 1982 to December 31, 2011

II. Search Queries

[Chapter 1] Prevention

- **CQ1** Does interferon therapy effectively prevent chronic hepatitis C infection from developing into cancer? [PubMed]

  
  
  #3 #1 or #2

- **CQ2** Does liver support therapy effectively prevent HCC? [PubMed]

  
  
  #3 #1 or #2

- **CQ3** Does antiviral therapy against chronic hepatitis B effectively prevent HCC? [PubMed]

Chapter 2: Diagnosis and Surveillance

- **CQ4 Who are eligible candidates for surveillance? [PubMed]**
  
  

- **CQ5 Does surveillance improve prognosis? [PubMed]**

- **CQ6 What methods are used in surveillance? [PubMed]**

- **CQ7 When examining atypical liver nodules using dynamic CT or dynamic MRI, what size (cm) lesions should be examined? [PubMed]**

- **CQ8 Is it useful to measure two or more tumor markers for diagnosing HCC? [PubMed]**

266/309

#3     #1 or #2

• **CQ9 Is tumor marker measurement an effective post-treatment indicator for HCC? [PubMed]**


#3     #1 or #2

• **CQ10 What are the best tests for diagnosing early-stage HCC in patients with cirrhosis? [MEDLINE]**

S1     LIVER CIRRHOSIS! OR (LIVER OR LIVERS OR HEPATIC) (3N) CIRRHO? OR CHRONIC? (3N) LIVER (2W) (DISEASE? OR DISORDER?)

S2     (WELL () DIFFERENTI? OR SMALL? OR HYPOVASCULAR? OR ADENOMATOUS? (3N) HYPERPLASIA? OR DYSPLASTI? (3N) NODUL?) /TI

S3     (BORDERLIN? OR NODUL?) /TI

S4     INTERNATIONAL? (3N) CONSENS? (3N) GROUP? (3N) HEPATOCEL? () NEOPLAS?

S5     FOCAL NODULAR HYPERPLASIA!


S8     DISEASE PROGRESSION!

S9     DI/DE OR US/DE OR RA/DE OR RI/DE OR DIAGNOSTIC IMAGING!

S10    CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING?

S11    OUTCOME? /TI

S12    SENSITIVI? OR ACCURACI? OR SPECIFICI? OR ROC

S13    (S1/DE OR S1/TI OR S2 OR S3 OR S4 OR S5) * (S6 + S7 + S8) * (S9 + S10)

S14    S13 * ((LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?) /TI AND S11


S16    (LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?) /TI AND S13 AND (S15 + S10/TI)
**CQ11 What are the best tests for diagnosing typical HCC in high-risk HCC patients? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL+HAEPATOCELL+HEPATO+HAEPATO+LIVER)+(CELL+CELLULA)+(W)(NEOPLASM+CANCER+TUMOR+TUMOUR+CARCINOM)/TI+(HEPATOMA?+HAEPATOMA?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2 S1/HUMAN+(S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP=20070701:20111231

S5 (DIAGNOS? OR DETECT? OR IDENTI? OR TEST? OR IMAG?)/TI

S6 SENSITIVIT?+SPECIFICIT?+ACCURAC?

S7 S4*S5*S6

S8 (USEFUL? OR EFFICAC? OR EFFECTIV?)/TI

S9 MT/DE

S10 S7*S8*S9

S11 S7*S8+S7*S9

**CQ12 Is angiography necessary before HCC treatment? [MEDLINE]**

**CQ13 Is CTAP/CTHA necessary before HCC treatment? [MEDLINE]**

S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE

S2 (CLINICAL+Critical) (1W) (PATH+PATHS+PATHWAY?) /TI+ (CLINICAL+TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+(GOOD (1W) CLINICAL (1W) PRACTICE?) /TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4 DT=META-ANALYSIS+META-ANALYSIS/DE+(META () ANALY?+METAANAL?) /TI

**CQ14 What test methods are useful for diagnosing liver tumors in patients with decreased kidney and liver functions? [MEDLINE]**


S2 NEPHROPATH? OR CIRRH? OR NEPHRITI?

S3 JAUNDIC? OR HYPERBIL? OR (BIL OR BILI?) (3N) (RISE? OR RISING? OR ELEVAT? OR HIGH? OR INCREAS?)


S5 GD (EOB) DTPA + GADOXETIC (3W) ENHANCE? (3W) (MRI OR MR)
**CQ15 How should contrast media be used for the diagnostic imaging of HCC?**

**[MEDLINE]**


- **S2** S1 / HUMAN+ (S1 NOT ANIMALS)

- **S3** S2 / ENG

- **S4** S3 AND UP = 20070701 ; 20111231


- **S7** CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE) (IN) (MEDIA?+DYE?+MATERIAL?+AGENT?)
CQ16 Are head MRI, chest CT, bone scintigraphy, and FDG-PET necessary for determining the stage of HCC? [MEDLINE]

CQ17 Does contrast-enhanced ultrasound improve the ability to diagnose HCC? [MEDLINE]
MEDICINE/DE
S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI
S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)
S4 DT = META-ANALYSIS + META-ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI
S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI
S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W) CENT?) / TI
S10 CASE-CONTROL STUDIES! + MATCHED-PAIR ANALYSIS / DE + CASE () CONTROL / TI
S11 S1 : S10
S13 S12 / HUMAN + (S12 NOT ANIMALS)
S14 S13 / ENG
S15 S14 * UP = 20070701 : 20111231
S16 S11 * S15
S18 CONTRAST MEDIA! + (CONTRAST + RADIOPAQUE) (1N) (MEDIA? + DYE? + MATERIAL? + AGENT?) / TI
S19 (DI OR DIAGNOSIS! OR RA OR RI OR US) / DF OR DIAGNOS? / TI
S20 S16 * S17 * S18 * S19
S21 S20 * S19 / MAJ
CQ18 Is contrast-enhanced ultrasound useful for determining the outcomes of local therapy and TACE? [MEDLINE]

S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DF


S3 (SYSTEMATIC + QUANTITATIVE + METHODOLOGIC + COLLABORATIVE + INTEGRATIVE) (1W) (REVIEW? + OVERVIEW?) /TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT=META-ANALYSIS + META-ANALYSIS/DF + (META () ANALY? + METAANAL?) /TI


S7 DT=CLINICAL TRIAL? + CLINICAL TRIALS! + (TRIAL? + STUDY + STUDIES) /TI

S8 COHORT STUDIES! + COHORT? /TI

S9 DT=MULTICENTER STUDY + MULTICENTER STUDIES /DF + (MULTICENT? + MULTI (W) CENT?) /TI

S10 CASE−CONTROL STUDIES! + MATCHED−PAIR ANALYSIS /DF + CASE () (CONTROL + COMPARISON? + REFERENT? + REFERRENT?) /TI + RETROSPECTIVE? /TI

S11 S1 : S10


S13 S12/HUMAN + (S12 NOT ANIMALS)

S14 S13/ENG

S15 S14*UP=20070701 : 20111231

S16 S11*S15


S18 (ANTITHROMBOTIC + ANTI (1W) THROMBOTIC) (1W) REGIMEN? + EMBOLIZE? +
(EMBOL? + THROMBUS?) (1N) FORM? + EMBOLIZATION, THERAPEUTIC! + TAE + TACE 
+ ((TRANSCATHETER? + TRANSARTER? + TRANS) (W) (CATHETER? + ARTER? ?)) (3N) 
(EMBOLI? + CHEMOEMBOLI?)

S19 (LOCAL + TOPICAL) (3N) (REMED? + THERAP? + TREATMENT?)

(TREATMENT? + THERAP? + CURATIVE?)

S21 S16 * S17 * (S18 + S19) * S20

S22 S16 * S17 * (S18 + S19)

S23 S15 * S17 * (S18 + S19) * S20

[Chapter 3] Surgery

- **CQ19 What assessment factors are appropriate for evaluating liver function prior to heptectomy?**

What are the indications for surgery from the perspective of liver function? [MEDLINE]

S1 CARCINOMA, HEPATOCELLULAR /
/TI * LIVER NEOPLASMS!

S2 S1 / HUMAN + (S1 NOT ANIMALS)

S3 S2 / ENG

S4 S3 * UP = 20070701 : 20111231


S6 S4 NOT S5

S7 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) 
/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE 
GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8 S4 * S7

S9 S6 + S8

ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENULCENAT?)

S11 HEPATECTOMY?

S12 S9 AND (S10 OR S11)

S13 PREOPERAT? + PRESURGER? + (BEFORE + PRE + PRIOR) (W) (OPERAT? + SURGER?)

S14 PREDICT? / DE AND SURGERY / DE

S15 S13 + S14

S16 S15 (3N) (ASSESSMENT? OR TEST? ?)

S17 S15 AND (HEPAT? OR LIVER) (3N) (FUNCTION? OR STATUS?)

S18 S12 AND (S16 OR S17)
• CQ20 What is the standard surgical procedure for hepatectomy? [MEDLINE]
S2 S1/HUMAN+ (S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND PY = >1982 AND UP = 19830906 : 20111231
S5 LIVER NEOPLASMS! (L) SU
S6 HEPATECTOMY!
S8 (NEW? OR STANDARD? OR GOLDSTANDARD? OR APPROACH? OR METHOD? OR TECHNI?) /TI
S9 HEPATECTOMY! (L) METHODS
S10 (S5+S6) *S7*S8
S11 (SEGMENT? OR SUBSEGMENT?) /TI (S5+S6) *S8
S12 S4* (S9+S10+S11)

• CQ21 What are the indications for hepatectomy in terms of tumor condition? [MEDLINE]
S2 S1/HUMAN+ (S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND PY = >1982 AND UP = 19830906 : 19900630
S5 S3 AND PY = >1982 AND UP = 19900630 : 19950630
S6 S3 AND PY = >1982 AND UP = 19950630 : 20000630
S7 S3 AND PY = >1982 AND UP = 20000630 : 20050630
S8 S3 AND PY = >1982 AND UP = 20050630 : 20111231
S9 S4 : S8
S11 S9 NOT S10
S12 DT=META—ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13 S9*S12
S14 S11+S13
S15 HEPATECTOMY!
S16 LIVER NEOPLASMS (L) SU


S19 (EFFECTIV? + BENEFIT?) (3N) (PATIENT + PATIENTS + SUBJECT + SUBJECTS + CASE + CASES)


S21 S14 * (S15 + S16 + 17) * (S18 + S19 + S20)

S22 S21 *

CQ22 What are the prognostic factors after hepatectomy? [MEDLINE]

S1 DT= (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN= (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT= META—ANALYSIS + META—ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI


S7 DT= CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI


S9 DT= MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W CENT?) / TI

S10 CASE—CONTROL STUDIES! + MATCHED—PAIR ANALYSIS / DE + CASE () CONTROL / TI

S11 S1 : S10

276/309
CQ23 Does the size of the resection margin affect prognosis? [MEDLINE]

- **S1**
  - `DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES) / DE+RECOMMENDATION? / TI+GUIDELINE? / TI+CLINICAL PROTOCOLS / DE+PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE
- **S2**
  - `(CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI+CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI
- **S3**
  - `(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI+PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)
- **S4**
  - `DT=META-ANALYSIS + META-ANALYSIS / DE+ (META () ANALY?+METAANAL?) / TI
- **S5**
- **S6**
- **S7**
- **S8**
EPIDEMIOLOGIC STUDIES!

S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES/DE + (MULTICENT? + MULTI (W) CENT?) /TI

S10 CASE–CONTROL STUDIES! + MATCHED–PAIR ANALYSIS/DE + CASE () CONTROL/TI

S11 S1 : S10


S13 S12/ HUMAN + (S12 NOT ANIMALS)

S14 S13/ ENG

S15 S14/ UP = 20070701 : 20111231

S16 S11 * S15


S18 HEPATECTOMY?

S19 S16 AND (S17 OR S18)

S20 SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION? OR MARGIN?


S22 S19 AND S20 AND S21

S23 S22 AND (CARCINOMA, HEPATOCELLULAR!) / MAJ

- CQ24 Does anatomical hepatic resection affect prognosis? [MEDLINE]

S1 DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE–BASED MEDICINE / DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD) (1W) CLINICAL (1W) PRACTICE? / TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT = META–ANALYSIS + META–ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI

S5 DT = RANDOMIZED CONTROLLED TRIAL + RANDOMIZED CONTROLLED TRIALS / DE + RANDOM ALLOCATION / DE + RANDOM? + DOUBLE–BLIND METHOD / DE + SINGLE–


S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) / TI


S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT?+MULTI (W) CENT?) / TI

S10 CASE–CONTROL STUDIES! + MATCHED–PAIR ANALYSIS / DE + CASE () CONTROL / TI

S11 S1 : S10


S13 S12/HUMAN + (S12 NOT ANIMALS)

S14 S13/ENG

S15 S14*UP=20070701 : 20111231

S16 S11*S15


S19 S16*S17*S18

• **CQ25 Is proactive, perioperative administration of blood products recommended? [MEDLINE]**


S2 S1/HUMAN + (S12 NOT ANIMALS)

S3 S2/ENG

S4 S3*UP=20070701 : 20111231


S6 PERIOPERAT?+INTRAOPERAT?+ (PERI+INTRA+DURING?) (3N) (OP+SURGER??++
CQ26 Does hepatic pedicle clamping and decreased central venous pressure decrease bleeding during liver resection? [MEDLINE]


S17 S14*S15*S16

S18 PEDICL? (1W) (CLAMP? + OCCLUS?) + IPO + HPC + PRINGL?

S19 ((CENTRAL? (1W) VENOUS? (1W) PRESSUR?) + CVP? (3N) (REDUC? + LOW + DECREAS? + FALL?? + DROP???)

S20 S17* (S18 + S19)

S21 PEDICL? (1W) (CLAMP? + OCCLUS?) + IPO + HPC + PRINGL? + PORTAL () TRIAD () CLAMP? + PTC

S22 S17* (S19 + S21)

- **CQ27 Is abdominal drain placement necessary for hepatectomy? [MEDLINE]**

S1 DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?)/DE + RECOMMENDATION?/TI + GUIDELINE? /TI + CLINICAL PROTOCOLS /DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE/DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? /TI + CARE (1N) PLANNING? /TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLINIC + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT = META-ANALYSIS + META-ANALYSIS/DE + (META? ANALY? + METAANAL?) /TI


S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT + WSCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) /TI


S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES/DE + (MULTICENT? + MULTI (W)
CENT? /TI
S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS／DE+CASE () CONTROL／TI
S11 S1 : S10
S12 S11／HUMAN+(S12 NOT ANIMALS)
S13 S12／ENG
S14 S13 AND PY = >1982 AND UP = 19820906 : 20111231
S16 ABDOM?（2N）DRAIN?
S17 S14＊S15＊S16

- CQ28 Does neoadjuvant therapy improve prognosis after hepatectomy?

[MEDLINE]
S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES)／DE+RECOMMENDATION／TI+GUIDELINE／TI+CLINICAL PROTOCOLS／DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE／DE
S2 (CLINICAL + CRITICAL) （1W）（PATH + PATHS + PATHWAY?）／TI+(CLINICAL + TREATMENT?) （2N）PROTOCOL?／TI+CARE （1N）PLANNING?／TI+(GOOD （1W）CLINICAL （1W）PRACTICE?)／TI
S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) （1W）（REVIEW OR OVERVIEW?）／TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4 DT=META-ANALYSIS+META-ANALYSIS／DE+（META （） ANALY?+METAANAL?）／TI
S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS!／DE + （PHASE + CLINICAL + PILOT + ESCALAT?+DOSE） （2W）（TRIAL?+STUDY+STUDIES）／TI
S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES／DE+（MULTICENT?+MULTI （W） CENT?）／TI

282/309
CASE–CONTROL STUDIES! + MATCHED–PAIR ANALYSIS／DE+CASE ／CONTROL／TI
S11  S1：S10
S13  S12／HUMAN+(S12 NOT ANIMALS)
S14  S13／ENG
S15  S14＊UP=20070701：20111231
S16  S11＊S15
S18  NEOADJUVANT?+NAC+NEO() ADJUVAN?
S21  S16＊S17＊(S18+S19+S20)
S23  S21＊S22
-  **CQ29 Does adjuvant therapy improve prognosis after hepatectomy?**
  [MEDLINE]
S1  DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)／DE+RECOMMENDATION?／TI+GUIDELINE／TI+CLINICAL PROTOCOLS／DE+PATIENT CARE PLANNING!+EVIDENCE–BASED MEDICINE／DE
S2  (CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)／TI+(CLINICAL+TREATMENT?) (2N) PROTOCOL?／TI+CARE (1N) PLANNING?／TI+(GOOD (1W) CLINICAL (1W) PRACTICE?)／TI
S3  (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W) (REVIEW? OR OVERVIEW?)／TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4  DT=META–ANALYSIS+META–ANALYSIS／DE+(META () ANALY?+METAANAL?)／TI
Does pretransplantation tumor downstaging improve the prognosis of liver transplantation? [MEDLINE]
CQ31 What are the criteria for liver transplantation in HCC patients?

MEDLINE

S1 CARCINOMA, HEPATOCELLULAR/DF +(HEPATOCELL+HAEPATOCELL+HEPATO+HAEPATO+LIVER) (W) (CELL++CELLULA?) (2N) (NEOPLASM+CANCER+TUMOR+TUMOUR+CARCINOM)/TI+ (HEPATOMA?+HAEPATOMA?) /TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2 S1/HUMAN+(S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP=20070701:20111231

S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE ( ) REPORT?/TI

S6 S4 NOT S5

S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8 S4*S7

S9 S6+S8

S10 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR TRANSPLAN?

S11 DOWN? () STAG? OR DOWNSTAG?

S12 S9*S10*S11

S13 PRE ( ) TRANSPLAN? OR PRETRANSPLAN? OR TRANSPLAN? (3N) (BEFOR? OR FOLLOW? OR AFTER? OR WAIT?)

S14 BRIDGING? OR ABLAT? OR RFA

S15 (LOCAL++LOCOREGION+LOC() REGION++TOPICAL OR BRIDG?) (3N) (THERAP?+TREAT?)

S16 TAE OR TACE OR (TRANSCATHETER? OR TRANSARTER?) (3N) (EMBOLI? OR CHEMOEMBOLI?)

S17 S13(5N) (S14+S15+S16)

S18 S9*S17

S19 S12+S18

- CQ31 What are the criteria for liver transplantation in HCC patients?
[Chapter 4] Percutaneous Local Ablation

- **CQ32** Who are eligible candidates for percutaneous ablation? [PubMed]
- **CQ33** How should the type of percutaneous ablation be selected? [PubMed]
- **CQ34** Does a combination of TACE and percutaneous ablation improve prognosis? [PubMed]
- **CQ35** Are fusion images obtained with contrast-enhanced ultrasound, computed tomography, and magnetic resonance imaging (MRI) useful guides for local therapy? [PubMed]


3. #1 or #2

- **CQ36** What type of diagnostic imaging is useful for determining the outcome of local therapy? [PubMed]


286/309

#3  #1 or #2

[Chapter 5] Transcatheter Arterial Chemoembolization (TACE)

- CQ37 Who are eligible for TACE/TAE? [MEDLINE]

S2 S1/HUMAN+ (S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND UP=20070701 : 20111231
S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE ? REPORT?/TI
S6 S4 NOT S5
S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC
S8 S4*S7
S9 S6+S8
S12 (EFFECTIV?+BENEFIT?) (3N) (PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
S13 INDICAT?/TI+INDICAT? (3N) (ETHANOL?+RFA+PEI+PMCT+ABLAT?)
S14 S9*S10* (S11 : S13)

- CQ38 What type of embolic material or anticancer agent should be used in TACE/TAE? [MEDLINE]


287/309
CQ39 How should repeat TACE/TAE be scheduled? [MEDLINE]
CQ40 What types of diagnostic imaging techniques are useful for determining the treatment outcome of TACE? [MEDLINE]


S1 AND S4 AND S5 AND S6 AND S7
[Chapter 6] Chemotherapy

• **CQ41 Who are eligible candidates for systemic chemotherapy? [MEDLINE]**

S1  DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

S2  (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

S3  (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4  DT = META-ANALYSIS + META-ANALYSIS / DE + (META (1) ANALY? + METAANAL?) / TI

S5  DT = RANDOMIZED CONTROLLED TRIAL + RANDOMIZED CONTROLLED TRIALS / DE +


S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI


S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W CENT?) ) / TI

S10 CASE-CONTROL STUDIES! + MATCHED-PAIR ANALYSIS / DE + CASE () CONTROL / TI

S11 S1 : S10


S13 S12 / HUMAN + (S12 NOT ANIMALS)

S14 S13 / ENG

S15 S14 AND UP = 20070701 : 20111231

S16 S11 * S15


S18 S16 * S17

S19 S17 / TI AND S18

S20 DRUG THERAPY! + DT / DF + ANTINEOPLASTIC AGENTS! (L) (TU + AD)

S21 S18 * S20

S22 S20 / MAJ AND S21

S23 S22 + S19


S25 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S26 S23 NOT S24

S27 S23 * S25

S28 S26 + S27
• CQ42 Does hepatic arterial infusion chemotherapy improve prognosis?
  [MEDLINE]
S2 S1/HUMAN+(S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND UP=20070701 : 20111231
S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
S6 DT=META-ANALYSIS or (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S7 S4 NOT S5
S8 S4*S6
S9 S7+S8
S11 S9*S10
S13 (INTRAARTER? OR ARTER?) (3N) (THERAP? OR CHEMOTHERAP? OR TREAT?)
S15 S11*(S12+13)*S14

• CQ43 Which chemotherapy regimens (drug regimens) are effective?
  [MEDLINE]
S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE
S2 (CLINICAL+CRITICAL) (1W) (PATH+PATHS+PATHWAY?) /TI+(CLINICAL+TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+(GOOD (1W) CLINICAL (1W) PRACTICE?) /TI
S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
S4 DT=META-ANALYSIS+META-ANALYSIS/DE+(META() ANALY?+METAANAL?) / TI
S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+ (PHASE+CLINICAL+PILOT+E SCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) / TI
S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) / TI
S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/ TI
S11 S1 : S10
S13 S12/HUMAN+ (S12 NOT ANIMALS)
S14 S13/ENG
S15 S14 AND UP=20070701 : 20111231
S16 S11*S15
S18 DRUG THERAPY!+DT / DF+ANTINEOPLASTIC AGENTS! (L) (TU+AD)
S19 S16* (S17/TI+S18/MAJ)
S20 S19*S12/TI
S21 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
S22 DT=META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT= PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S23 S20 NOT S21
S24 S20*S22
S25 S23+S24
• **CQ44 Is hormone therapy effective? [MEDLINE]**


S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP = 20070701 : 20111231


S6 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S7 S4 NOT S5

S8 S4*S6

S9 S7+S8


S12 TAMOXIFEN?+ADOPAN+EMALOOK+SOSHIGEN+TASUOMIN+NORXIFEN+NOLVADEX+PANLEEF+PHENOLURN+RESPOL+ICI (1W) 46474+ICI46474+ICI (1W) 47699+ICI47699+ZITAZONIUM

S13 S10 : S12

S14 S9*S13

• **CQ45 What are the predictive and prognostic factors for the treatment outcomes of chemotherapy (drug therapy)? [MEDLINE]**


S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP = 20070701 : 20111231


S6 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S7 S4 NOT S5
**CQ46 How should the treatment outcome of chemotherapy be determined?**

[MEDLINE]


S2 S1/HUMAN + (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY = > 1982 AND UP = 19830906 : 19900630

S5 S3 AND PY = > 1982 AND UP = 19900630 : 19950630

S6 S3 AND PY = > 1982 AND UP = 19950630 : 20000630

S7 S3 AND PY = > 1982 AND UP = 20000630 : 20050630

S8 S3 AND PY = > 1982 AND UP = 20050630 : 20111231

S9 S4 : S8


S11 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S12 S9 NOT S10

S13 S9*S11

S14 S12+S13


S16 RESPON? (2N) (CRITERIA? + EVALUAT?)

S17 S14*S15*S16
CQ47 What are the adverse effects of chemotherapy, and how should they be treated? [MEDLINE]


S2 S1 / HUMAN / (S1 NOT ANIMALS)

S3 S2 / ENG

S4 S3 AND PY => 1982 AND UP = 19900630

S5 S3 AND PY => 1982 AND UP = 19950630

S6 S3 AND PY => 1982 AND UP = 20000630

S7 S3 AND PY => 1982 AND UP = 20050630

S8 S3 AND PY => 1982 AND UP = 20111231

S9 S4 / S8

S10 DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

S11 (CLINICAL + CRITICAL?) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

S12 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE?) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW!? + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S13 DT = META-ANALYSIS + META-ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI


S15 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S16 S9 NOT S14

S17 S9 * S15

S18 S16 + S17


S20 ANTINEOPLASTIC AGENTS! (L) (AE + PO + CT + TO)

S21 (ADVERS? + SAFETY + TOXIC?) / TI
[Chapter 7] Radiation Therapy

CQ48 Is 3D conformal radiation therapy useful for HCC? [MEDLINE]

DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

DT = (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

DT = (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

DT = META-ANALYSIS + META-ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI


DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W) CENT?) / TI

CASE–CONTROL STUDIES! + MATCHED–PAIR ANALYSIS / DE + CASE () CONTROL / TI

CASE–CONTROL STUDIES! + MATCHED–PAIR ANALYSIS / DE + CASE () CONTROL / TI

S11 S1 : S10


S13 S11 * S12

HUMAN OR (S13 NOT ANIMALS)

ENG
CQ49 Is stereotactic body radiation therapy useful for HCC? [MEDLINE]


S2 STEREOTACTIC (3N) (RADIOThERAP? OR RADIosURG? OR RADIATION? OR IRRADIAT?)


S4 SBRT OR SBT OR SRT OR STEREOtACTIC OR PINPOINT?

S5 DT=REVIEW?

S6 S1 NOT S5

S7 S6/ HUMAN+ (S6 NOT ANIMALS)

S8 S7/ ENG

S9 S8 AND PY=> 1982 AND UP=19980906 : 19900630

S10 S8 AND PY=> 1982 AND UP=19900630 : 19950630

S11 S8 AND PY=> 1982 AND UP=19950630 : 20000630

S12 S8 AND PY=> 1982 AND UP=20000630 : 20050630

S13 S8 AND PY=> 1982 AND UP=20050630 : 20111231

S14 S9: S13

S15 S14/S2

S16 S14*S3*S4

S17 S15+S16

CQ50 Is particle radiation therapy [proton therapy, heavy particle (carbon ion) radiation therapy] useful against HCC? [MEDLINE]


S2 (HEAVY OR CARBON? OR PROTON? OR PARTICL?) (2N) (THERAP? OR ION OR IONS OR BEAM OR BEAMS OR IRRADIAT? OR RADIOISOTOP?)}
CQ51 Is radiation therapy indicated for distant metastases from hepatocellular carcinoma? [MEDLINE]

DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLINICAL) / DE + CONTROL? (1W) TRIAL? / STUDY / TI

S4 DT = META-ANALYSIS + META-ANALYSIS / DE + (META (1W) ANALY? + METAANAL?) / TI


S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI


S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W)
CENT?
S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS／DE+CASE () CONTROL／TI
S11 S1 : S10
S12 CARCINOMA, HEPATOCELLULAR! + (HEPATOCELL? + HAEPATOCELL? + (HEPATO +
HAEPATO)) (W) (CELL?? + CELLULA?) (2N) (NEOPLASM? + CANCER? + TUMOR? +
TUMOUR? + CARCINOM?)／TI+ (HCC+HCCS)／TI*LIVER NEOPLASMS!
S13 S11*S12
S14 S13／HUMAN OR (S13 NOT ANIMALS)
S15 S14／ENG
S16 S15 AND UP=20070701 : 20111231
S17 RADIOThERApY! + RT／DF + RADIoCHEm? + CHEMORADIO? + IRRADIAT? +
RADIOThERA?+RADiAT?+BRaCHYTHER?+RADIosURGE?
S18 S16*S17
S20 EFFECACY OR SURVIVAL? OR RESPONSE () (RATE OR RATES) OR LOCAL () CONTROL?
OR SAFETY OR ADVERS? (1W) (EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR
FEASIBILITy
S21 S19+S20
S22 S18*S21
S23 S1 : S6
S24 S23／HUMAN OR (S23 NOT ANIMALS)
S25 S24／ENG
S26 S25 AND UP=20070701 : 20111231
S27 (RADIOThERApY! + RT／DF + RADIoCHEm? + CHEMORADIO? + IRRADIAT? +
RADIOThERA?+RADiAT?+BRaCHYTHER?+RADIosURGE?) *METASTA?
S28 S16*S27
S29 S26*S27
S30 METASTA? (4N) (RADIOThERApY?+CHEMORADIO?+RADIOCHEm?+IRRADIAT?+RADiAT?
+BRaCHYTHER?+RADIosURG?)
S31 S16*S30
S32 S26*S30
S33 CENTRAL NERVOUS SYSTEM NEOPLASMS! (L) SECONDARY OR BONE NEOPLASMS! (L)
SECONDARY
S34 (BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?) (4N) METASTA?
S35 S28+S31
S36 (S29+S32) ＊ (S33+S34)
S38 S35+S37
S39 S34／TI AND S36
S40 S39+S35
[Chapter 8] Post-Treatment Surveillance and Prevention and Treatment of Recurrence

- **Q52 How should patients be followed up after hepatectomy and percutaneous ablation? [MEDLINE]**


S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY = > 1982 AND UP = 19830906 : 19900630

S5 S3 AND PY = > 1982 AND UP = 19900630 : 19950630

S6 S3 AND PY = > 1982 AND UP = 19950630 : 20000630

S7 S3 AND PY = > 1982 AND UP = 20000630 : 20050630

S8 S3 AND PY = > 1982 AND UP = 20050630 : 20111231

S9 S4 : S8


S11 S9 NOT S10

S12 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9 * S12

S14 S11 + S13

S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU


S18 FOLLOWUP OR FOLLOW () UP

S19 S14 * (S15 + S16 + S17)

S20 S18 * S19


S23 S18 /TI * S19


S25 (S21 + S22) (4N) S18

301/309
CQ52 How should patients be followed up after hepatectomy and percutaneous ablation? [MEDLINE]


S2 S1/HUMAN + (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY = > 1982 AND UP = 19900630

S5 S3 AND PY = > 1982 AND UP = 19950630

S6 S3 AND PY = > 1982 AND UP = 20000630

S7 S3 AND PY = > 1982 AND UP = 20050630

S8 S3 AND PY = > 1982 AND UP = 20111231

S9 S4 : S8


S11 S9 NOT S10

S12 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9 * S12

S14 S11 + S13

S15 (PEI OR PEIT OR EIT) AND ETHANOL??

S16 MICROWAVES /DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)

S17 (PMCT OR MCT) AND MICROWAVE?

S18 ELECTROCOAGULATION! OR RADIO WAVES /DE OR ABLAT?

S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA

S20 PEI* (PERCUTANEOUS? + ETHANOL?) + PEIT + (PERCUTANEOUS? + TRANSDERMAL?) (2N) (ETHANOL? OR ETHYL () ALCOHOL?)

S21 PMCT + PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?

S22 RFA + (RADIO (1W) (FREQUENC? + WAVE?) + RADIOFREQUEN?) (2N) ABLAT?


S24 S15 : S23

S25 S14 * S24

S26 FOLLOWUP OR FOLLOW () UP

S27 S25 * S26

S28 S26 /TI * S27
What are the effective methods for preventing recurrence after hepatectomy and percutaneous ablation? [MEDLINE]


S2 S1/HUMAN+ (S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND PY = > 1982 AND UP = 19900630
S5 S3 AND PY = > 1982 AND UP = 19950630
S6 S3 AND PY = > 1982 AND UP = 20000630
S7 S3 AND PY = > 1982 AND UP = 20050630
S8 S3 AND PY = > 1982 AND UP = 20111231
S9 S4 : S8
S11 S9 NOT S10
S12 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW? /TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13 S9 * S12
S14 S11 + S13
S15 HEPATECTOMY!
S16 LIVER NEOPLASMS (L) SU
S18 RECURREN?
S19 NEOPLASM RECURRENCE, LOCAL! (L) PC
S20 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYLACL?)
S21 S14 * (S15 + S16 + S17) * S18
CQ53 What are the effective methods for preventing recurrence after hepatectomy and percutaneous ablation? [MEDLINE]


S2 S1/HUMAN+(S1 NOT ANIMALS)
S3 S2/ENG
S4 S3 AND PY=>1982 AND UP=19830906:19900630
S5 S3 AND PY=>1982 AND UP=19900630:19950630
S6 S3 AND PY=>1982 AND UP=19950630:20000630
S7 S3 AND PY=>1982 AND UP=20000630:20050630
S8 S3 AND PY=>1982 AND UP=20050630:20111231
S9 S4:S8
S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
S11 S9 NOT S10
S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
S13 S9*S12
S14 S11+S13
S15 (PEI OR PEIT OR EIT) AND ETHANOL??
S16 MICROWAVES/DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)
S17 (PMCT OR MCT) AND MICROWAVE?
S18 ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?
S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA
S20 PEI* (PERCUTANEOUS?+ETHANOL?) + PEIT+ (PERCUTANEOUS?+TRANSDERMAL?)
(2N) (ETHANOL? OR ETHYL () ALCOHOL?)
S21 PMCT+PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?
S22 RFA+ (RADIO (1W) (FREQUENC?+WAVE?) + RADIOFREQUEN?) (2N) ABLAT?
S24 S15:S23
S25 RECURREN?
S26 NEOPLASM RECURRENCE, LOCAL! (L) PC
S27 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYLA?)

304/309
CQ54 What are the effective methods for preventing recurrence after liver transplantation? [MEDLINE]


S2 S1 / HUMAN + (S1 NOT ANIMALS)

S3 S2 / ENG

S4 S3 AND PY = > 1982 AND UP = 19900630

S5 S3 AND PY = > 1982 AND UP = 19900630

S6 S3 AND PY = > 1982 AND UP = 19900630

S7 S3 AND PY = > 1982 AND UP = 20000630

S8 S3 AND PY = > 1982 AND UP = 20000630

S9 S4 : S8


S11 S9 NOT S10

S12 DT = META–ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9 * S12

S14 S11 + S13

S15 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR LIVER? (3N) TRANSPLANT?

S16 RECURREN?

S17 NEOPLASM RECURRENT, LOCAL (L) PC

S18 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYL? A)

S19 IMMUNOSUPPRESSIVE AGENTS! (L) TU

S20 SURVIV? (3N) (INCREAS? OR PROLONG? OR IMPROV?)

S21 (PREDICT? OR DETECT?) (3N) (PROGRES? OR RECURREN?)
CQ55 What are the effective treatments against recurrence after hepatectomy? [MEDLINE]


S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906:19900630

S5 S3 AND PY=>1982 AND UP=19900630:19950630

S6 S3 AND PY=>1982 AND UP=19950630:20000630

S7 S3 AND PY=>1982 AND UP=20000630:20050630

S8 S3 AND PY=>1982 AND UP=20050630:20111231

S9 S4:S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9*S12

S14 S11+S13

S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU


• CQ56 What treatments are effective against recurrence after percutaneous ablation? [MEDLINE]


S2 S1 / HUMAN + (S1 NOT ANIMALS)

S3 S2 / ENG

S4 S3 AND PY = > 1982 AND UP = 19830906 : 19900630

S5 S3 AND PY = > 1982 AND UP = 19900630 : 19950630

S6 S3 AND PY = > 1982 AND UP = 19950630 : 20000630

S7 S3 AND PY = > 1982 AND UP = 20000630 : 20050630

S8 S3 AND PY = > 1982 AND UP = 20050630 : 20111231

S9 S4 : S8


S11 S9 NOT S10

S12 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW? OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9 * S12

S14 S11 + S13

S15 (PEI OR PEIT OR EIT) AND ETHANOL??

S16 MICROWAVES / DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)
S17 (PMCT OR MCT) AND MICROWAVE?
S18 ELECTROCOAGULATION! OR RADIO WAVES / DE OR ABLAT?
S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA
S20 PEI* (PERCUTANEOUS?+ETHANOL?) + PEIT + (PERCUTANEOUS?+TRANSDERMAL?)
   (2N) (ETHANOL? OR ETHYL () ALCOHOL?)
S21 PMCT + PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?
S22 RFA + (RADIO (1W) (FREQUENCY?+ WAVE?) + RADIOFREQUEN?) (2N) ABLAT?
S23 (LOCAL + TOPICAL + LOCOREGIONAL? OR LOCO () REGIONAL?) (3N) (REMED? +
S24 S15 : S23
S25 S14 * S24
S26 (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR
   ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR
   REGIONAL? OR TOPICAL?) (4N) (AFTER OR FOLLOW?)
S27 POST () (RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL?
   OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)
S28 (S26 + S27) (4N) RECURREN?
S29 NEOPLASM RECURRENCE, LOCAL! (L) (TH + DT + RT + SU)
S30 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR
   EFFICIEN? OR SUPERIOR?) / TI
S31 S25 * S28
S32 S29 * S31
S33 S30 * S31
S34 RECURREN? / TI OR NEOPLASM RECURRENCE, LOCAL!
S35 TU / DE
   EFFICIEN? OR SUPERIOR?) (4N) S28
S37 S31 * S36
S38 S31 * S34 * S35
S39 (AFTER OR FOLLOW?) (1W) (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR
   MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR
   LOCAL? OR REGIONAL? OR TOPICAL?)
S40 RECURREN? (3W) S39
S41 S40 * S31 * (S29 + S30)
S42 S32 + S33 + S37 + S38 + S41

- **CQ57 What treatments are effective against recurrence after liver transplantation? [MEDLINE]**
S1 CARCINOMA, HEPATOCellular / DF + (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+
   HAEPATO?+LIVER?) (W) (CELL?+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?
LIVER NEOPLASMS!

S1 HUMAN+ (S1 NOT ANIMALS)

S2 S1/ENG

S3 S2/EN

S4 S3 AND PY => 1982 AND UP = 19830906 : 19900630

S5 S3 AND PY => 1982 AND UP = 19900630 : 19950630

S6 S3 AND PY => 1982 AND UP = 19950630 : 20000630

S7 S3 AND PY => 1982 AND UP = 20000630 : 20050630

S8 S3 AND PY => 1982 AND UP = 20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)

S13 S9* S12

S14 S11 + S13

S15 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR LIVER? (3N) TRANSPLANT?

S16 S14*S15

S17 NEOPLASM RECURRENCE, LOCAL! (L) (TH+DT+RT+SU)

S18 RECURREN? (4N) ((FOLLOW? OR AFTER) (4N) TRANSPLAN? OR POSTTRANSPLAN? OR POST () TRANSPLAN?)

S19 S16*S17

S20 S16*S18/TI


S22 S20 AND S21


S24 S23*S16

S25 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!

S26 TU/DE

S27 S16*S25*S26

S28 S19+S22+S24+S27